Event Group
Event Groups are part of the Adverse Events Module within the Results Section. They provide a way to organize and summarize adverse event data by grouping related events together.
Each Event Group typically represents a category or class of adverse events and includes statistical information such as the number of participants affected and at risk for different event types: deaths, serious events, and other events.
Event Group path is as follows:
Study -> Results Section -> Adverse Events Module -> Event Group
Event Group
Ignite Creation Date:
2025-12-24 @ 5:04 PM
Ignite Modification Date:
2025-12-25 @ 2:43 PM
NCT ID:
NCT03644550
Group ID:
EG000
Title:
1/LMB- 100+Pembrolizumab
Description:
LMB-100 administered in cycles 1 and 2 + pembrolizumab administered in subsequent cycles.
LMB-100 140mcg/kg Intravenous infusion (IVI), Days 1, 3, 5 in cycles 1, 2. Pembrolizumab 200mg IVI, every (Q) subsequent cycle on Day 1.
LMB-100: Given intravenous (IV) at recommended phase 2 dose (RP2D) on days 1, 3 and 5 of two (2) 21 day cycles (i.e. RP2D was determined in a previous phase I trial).
Pembrolizumab: Given intravenous (IV) at approved dose on day 1 of each 21 day cycle, starting with cycle 3, for up to 2 years with the option of a second course for patients meeting criteria.
Deaths Number Affected:
9
Deaths Number At Risk:
None
Serious Number Affected:
14
Serious Number At Risk:
18
Other Number Affected:
18
Other Number At Risk:
18
Study:
NCT03644550
Results Section:
NCT03644550
Adverse Events Module:
NCT03644550